CAS 220620-09-7|Tigecycline

Introduction：Basic information about CAS 220620-09-7|Tigecycline, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Tigecycline BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Customs
6. Synonyms

Common Name	Tigecycline
CAS Number	220620-09-7	Molecular Weight	585.649
Density	1.5±0.1 g/cm3	Boiling Point	890.9±65.0 °C at 760 mmHg
Molecular Formula	C₂₉H₃₉N₅O₈	Melting Point	164-166°C
MSDS	/	Flash Point	492.6±34.3 °C
Symbol	GHS07, GHS08	Signal Word	Danger

Names

Name	tigecycline
Synonym	More Synonyms

Tigecycline BiologicalActivity

Description	Tigecycline is a first-in-class, broad spectrum antibiotic with activity against antibiotic-resistant organisms.Target: AntibacterialTigecycline is active against a broad range of gram-negative and gram-positive bacterial species including clinically important multidrug-resistant nosocomial and community-acquired bacterial pathogens. Tigecycline has been shown to inhibit the translation elongation step by binding to the ribosome 30S subunit and preventing aminoacylated tRNAs to accommodate in the ribosomal A site [1]. Tigecycline has also been found to be effective for the treatment of community- as well as hospital-acquired and ventilator-associated pneumonia and bacteremia, sepsis with shock and urinary tract infections. Tigecycline appears to be a valuable treatment option for the management of superbugs, especially where conventional therapy has failed [2].Fifteen patients received tigecycline for 16 episodes of CPKP infection. The main infections were pneumonia (31%), urinary tract infection (31%), peritonitis (20%), catheter-related bacteraemia (12%), and meningitis (6%). Most infections were complicated with severe sepsis (44%), septic shock (12%), and/or bacteraemia (19%). The daily maintenance dose of tigecycline was 200 mg in 10 episodes and 100 mg in 6 episodes. The overall 30-day mortality rate was 25%. Univariate analysis showed that mortality was significantly associated (p < 0.01) with mean APACHE II and SOFA scores and the presence of immunosuppression, but not with the tigecycline dose [3].
Related Catalog	Signaling Pathways >>Autophagy >>AutophagySignaling Pathways >>Anti-infection >>BacterialResearch Areas >>InfectionNatural Products >>Alkaloid
References	[1]. Seputiene V, et al. Tigecycline - how powerful is it in the fight against antibiotic-resistant bacteria? Medicina (Kaunas). 2010;46(4):240-8. [2]. Bhattacharya M, et al. Tigecycline. J Postgrad Med. 2009 Jan-Mar;55(1):65-8. [3]. Moreno BB, et al. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients. Scand J Infect Dis. 2013 Dec 20.

Description

Tigecycline is a first-in-class, broad spectrum antibiotic with activity against antibiotic-resistant organisms.Target: AntibacterialTigecycline is active against a broad range of gram-negative and gram-positive bacterial species including clinically important multidrug-resistant nosocomial and community-acquired bacterial pathogens. Tigecycline has been shown to inhibit the translation elongation step by binding to the ribosome 30S subunit and preventing aminoacylated tRNAs to accommodate in the ribosomal A site [1]. Tigecycline has also been found to be effective for the treatment of community- as well as hospital-acquired and ventilator-associated pneumonia and bacteremia, sepsis with shock and urinary tract infections. Tigecycline appears to be a valuable treatment option for the management of superbugs, especially where conventional therapy has failed [2].Fifteen patients received tigecycline for 16 episodes of CPKP infection. The main infections were pneumonia (31%), urinary tract infection (31%), peritonitis (20%), catheter-related bacteraemia (12%), and meningitis (6%). Most infections were complicated with severe sepsis (44%), septic shock (12%), and/or bacteraemia (19%). The daily maintenance dose of tigecycline was 200 mg in 10 episodes and 100 mg in 6 episodes. The overall 30-day mortality rate was 25%. Univariate analysis showed that mortality was significantly associated (p < 0.01) with mean APACHE II and SOFA scores and the presence of immunosuppression, but not with the tigecycline dose [3].

Related Catalog

Signaling Pathways >>Autophagy >>AutophagySignaling Pathways >>Anti-infection >>BacterialResearch Areas >>InfectionNatural Products >>Alkaloid

References

[1]. Seputiene V, et al. Tigecycline - how powerful is it in the fight against antibiotic-resistant bacteria? Medicina (Kaunas). 2010;46(4):240-8.

[2]. Bhattacharya M, et al. Tigecycline. J Postgrad Med. 2009 Jan-Mar;55(1):65-8.

[3]. Moreno BB, et al. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients. Scand J Infect Dis. 2013 Dec 20.

Chemical & Physical Properties

Density	1.5±0.1 g/cm3
Boiling Point	890.9±65.0 °C at 760 mmHg
Melting Point	164-166°C
Molecular Formula	C₂₉H₃₉N₅O₈
Molecular Weight	585.649
Flash Point	492.6±34.3 °C
Exact Mass	585.279846
PSA	205.76000
LogP	-1.30
Vapour Pressure	0.0±0.3 mmHg at 25°C
Index of Refraction	1.675
Storage condition	Amber Vial, -20°C Freezer

Safety Information

Symbol	GHS07, GHS08
Signal Word	Danger
Hazard Statements	H319-H360
Precautionary Statements	P201-P280-P305 + P351 + P338-P308 + P313
Hazard Codes	Xn
Safety Phrases	S24/25
RIDADR	UN 3077 9 / PGIII
WGK Germany	3
HS Code	3004909090

Customs

HS Code	3004909090

Synonyms

WAY-GAR 936

TIGECYCLINE POWDER

9-t-Butylglycylamido-minocycline hydrate

2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-((((1,1-dimethylethyl)amino)acetyl)amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-

Tigercycline

(4S,4aS,5aR,12aS)-9-{[(tert-butylamino)acetyl]amino}-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[[(1,1-dimethylethyl)amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-

2-NAPHTHACENECARBOXAMIDE

(4S,4aS,5aR,12aS)-9-[(N-tert-Butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

Glycylcycline

(4S,4aS,5aR,12aS)-4,7-Bis(dimethylamino)-3,10,12,12a-tetrahydroxy-9-{[N-(2-methyl-2-propanyl)glycyl]amino}-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-tetracenecarboxamide

2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[2-[(1,1-dimethylethyl)amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)-

Tygacil

MFCD00935753

Tigecycline

TIGECYCLINE GLYCYLCYCLINE

Tegecycline

Recommended......